Ubs Asset Management Americas Inc Phathom Pharmaceuticals, Inc. Transaction History
Ubs Asset Management Americas Inc
- $379 Billion
- Q1 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 99,744 shares of PHAT stock, worth $473,784. This represents 0.0% of its overall portfolio holdings.
Number of Shares
99,744
Previous 117,803
15.33%
Holding current value
$473,784
Previous $956,000
34.62%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding PHAT
# of Institutions
152Shares Held
66.6MCall Options Held
94KPut Options Held
55.5K-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.1MShares$48 Million3.99% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$35.5 Million12.73% of portfolio
-
Jennison Associates LLC7.04MShares$33.5 Million0.03% of portfolio
-
Invesco Ltd. Atlanta, GA3.65MShares$17.3 Million0.0% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$16.6 Million27.15% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $186M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...